

# In the News

## Update to Commercial and ACA Medical Benefit Product Coverage for Medical Mutual Plans

Effective Oct. 1, 2022, prior authorization will no longer be required for the following medications under the commercial and ACA medical benefit:

- Abraxane (paclitaxel protein-bound particles)
- Adcetris (brentximab vedotin)
- Alimta (pemetrexed)
- Faslodex (fulvestrant)
- Halaven (eribulin)
- Trisenox (arsenic trioxide)
- Velcade (bortezomib)
- Xgeva (denosumab)

For more information, please visit [Medmutual.com/For-Providers, Policies and Standards, Corporate Medical Policies.](https://www.medmutual.com/For-Providers-Policies-and-Standards-Corporate-Medical-Policies)